Remus Pharmaceuticals Limited (NSE:REMUS)

Market Cap	9.56B
Revenue (ttm)	6.20B
Net Income (ttm)	290.70M
Shares Out	11.78M
EPS (ttm)	32.61
PE Ratio	24.88
Forward PE	n/a
Dividend	0.75 (0.09%)
Ex-Dividend Date	Sep 18, 2025

Volume	1,600
Average Volume	3,975
Open	775.00
Previous Close	820.00
Day's Range	775.00 - 838.80
52-Week Range	775.00 - 1,416.45
Beta	0.65
RSI	33.91
Earnings Date	Aug 8, 2025

About Remus Pharmaceuticals

Remus Pharmaceuticals Limited engages in the marketing, trading, and distribution of pharmaceutical finished formulations and products in India and internationally. It is involved in trading of active pharmaceutical ingredient, as well as provides technical consultancy services to various distributors and contract manufacturing services. The company offers capsule, cream, eye drop, gel, infusion, inhalation, inhaler, injection, nail lacquer, nasal solution, nasal spray, nebulizer, ointment, ophthalmic, oral gel, oral solution, oral suspension, ...

• Industry: Drugs, Drug Proprietaries, and Druggists' Sundries
• Founded: 2015
• Employees: 48
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: REMUS

Financial Performance

In 2024, Remus Pharmaceuticals's revenue was 6.20 billion, an increase of 191.44% compared to the previous year's 2.13 billion. Earnings were 290.70 million, an increase of 34.98%.